Approaches to Common Clinical Scenarios in Hospitalized Stroke Patients

Similar documents
What s New in Stroke?

STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE

Medical Management of Ischemic Stroke: An Update. Siddharth Sehgal, MD Medical Director, TMH Neuroscience Center

Therapeutic Management Options for. Acute Ischemic Stroke Anna Rosenbaum, MD

9/5/14. Objectives. Atrial Fibrillation (AF)

AHA/ASA Ischemic Stroke Performance Measures

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence

Making the Case for CPG s Jean Luciano, MSN, RN, CNRN, SCRN, CRNP, FAHA Claranne Mathiesen, MSN, RN, CNRN, SCRN, FAHA

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations

The author has no disclosures

NOVEL ANTICOAGULANTS

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012

Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015

New Anticoagulants and GI bleeding

Anticoagulation Therapy Update

Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial

Duration of Dual Antiplatelet Therapy After Coronary Stenting

STROKE PREVENTION IN ATRIAL FIBRILLATION

To Bridge or Not to Bridge. Periop Anticoagulation Management. Don Weinshenker, MD Ambulatory Care Denver VAMC

The Anti coagulated Patient: The Cardiologist s View. February 28, 2015

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness SOGH April

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

EMS Management of Stroke. Deaver Shattuck, M.D. Brian Wiseman, M.D. Keith Woodward, M.D.

WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast

The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012

AR SAVES. INTRODUCTION AND UPDATES FOR ER PHYSICIANS. Nicolas Bianchi, MD. August 23 rd, 2012.

3/3/2015. Patrick Cobb, MD, FACP March 2015

ΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ. Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν

AHA/ASA Guideline. Guidelines for the Early Management of Patients with Acute Ischemic Stroke. A Guideline for Healthcare Professionals from the

2016 International Stroke Conference Hot Topics Lori M. Massaro, MSN, CRNP Kari Moore, MSN, AGACNP-BC

Stroke: Major Public Health Burden. Stroke: Major Public Health Burden. Stroke: Major Public Health Burden 5/21/2012

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History

Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines

Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE

New in Atrial Fibrillation

Anticoagulation For Atrial Fibrillation

Imaging of Acute Stroke. Noam Eshkar, M.D New Jersey Neuroscience Institute JFK Medical Center Edison Radiology Group

JHS Stroke Program JHS Annual Mandatory Education

Stroke Care First week

AHA/ASA Scientific Statement Oral Antithrombotic Agents for the Prevention of Stroke in Atrial Fibrillation

Stroke Risk Scores. CHA 2 DS 2 -VASc. CHA 2 DS 2 -VASc Scoring Table 2

AHA/ASA Scientific Statement

Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY

UPDATED INCLUSION AND EXCLUSION CRITERIA FOR IV TPA ADMINISTRATION ACUTE STROKE TREATMENT: AN UPDATE GOALS OF TALK

Accreditation and Certification Guidelines

4th Annual New York Stroke Conference Maximizing Stroke Quality of Care: Key Ingredients

Time of Offset of Action The Trial

Novel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute

Stroke Systems of Care

Stroke Prevention in Primary Care

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators

How to manage a patient who needs thrombolysis in acute stroke, ablation or angioplasty/stenting? Janet M McComb Freeman Hospital Newcastle upon Tyne

Disclosures. Georgia Facts. Stroke System Models. Telestroke. The World is Flat : A Brief Future of Acute Stroke Care

In recognition of the morbidity of recurrent brain ischemia,

Optimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015

New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation

4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285:

Level III Stroke Center Data Collection Requirements

Hot Topics: Current PFO Recommendations and Loop Monitoring/Cryptogenic Stroke.

STATEMENT OF STANDARD

Goals 6/6/2014. Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs. Ashkan Babaie, MD

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial

CHADS score of 5 or 6 Recent (within 3mo) stroke or TIA Rheumatic valvular heart disease CHADs score of 3 or 4

Anticoagulation in Atrial Fibrillation

Guidelines for Use of Clopidogrel (Plavix )

Bayer Pharma AG Berlin Germany Tel News Release. Not intended for U.S. and UK Media

Developing a Dynamic Team Approach to Stroke Care. Emergency Medical Services 2015

Emerging therapies for Intracerebral Hemorrhage

Atrial Fibrillation Peter Santucci, MD Revised May, 2008

Aspirin to Prevent Heart Attack and Stroke: What s the Right Dose?

UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient

STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach

Let s talk about: Stroke

Mechanical Embolectomy for Treatment of Acute Stroke. Original Policy Date

Stroke/Transient ischemic attack. Brandon Masi Parker OMS POPPF

Anticoagulants in Atrial Fibrillation

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania

DVT/PE Management with Rivaroxaban (Xarelto)

East Kent Prescribing Group

Evaluation of Ischemic Stroke and TIA

Current thrombolytic therapy in acute ischemic stroke is

Dabigatran (Pradaxa) Guidelines

Is this pt s brain dysfunction due to ischemia? Onset & progression of sx; location of deficit

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.

Committee Approval Date: September 12, 2014 Next Review Date: September 2015

Patient education for stroke prevention after a TIA

RR 0.88 (95% CI: ) P=0.051 (superiority) 3.75

Rivaroxaban in SPAF: Efficacy, safety and cardio-vascular profile. Hans Rickli, St.Gallen

Managing Anticoagulation for Atrial Fibrillation 2015

Palpitations & AF. Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust

Transcription:

Approaches to Common Clinical Scenarios in Hospitalized Stroke Patients Helmi L. Lutsep, MD Oregon Health & Science University Oregon Stroke Center Portland VA Medical Center DISCLOSURES Medscape Neurology Editorial Advisory Board

Objectives To review common consult questions: Which antiplatelet(s) to use when my patient is already on clopidogrel and has a recurrent stroke? Can my patient with a history of stroke stop his aspirin prior to surgery (and related questions)? Should I consider other approaches or is it just IV tpa now for acute stroke? Patient Case: Antithrombotics in Recurrent Stroke Mrs. H. has been on clopidogrel since having a TIA that occurred while she was on aspirin. A week ago she had a right frontal infarct. She has no known cardioembolic cause. What should her treatment be? 1) Keep her on clopidogrel 2) Add aspirin to the clopidogrel 3) Switch her to Aggrenox (ER dipyridamole and aspirin)

PRoFESS Trial Stroke prevention trial in 20,332 patients Aggrenox compared to clopidogrel Showed similar rates of recurrent stroke and major vascular events NEJM 2008;359:1238-51 Clopidogrel vs Aggrenox Data don t support switching from clopidogrel to Aggrenox except in certain cases (i.e., genetic non-responder)

Clopidogrel Plus Aspirin: When OK ASA Guidelines 2014 Symptomatic high grade intracranial stenosis for 3 months as per SAMMPRIS For patients with recent stroke or TIA (within 30 days) attributable to severe stenosis (70% 99%) of a major intracranial artery, the addition of clopidogrel 75 mg/d to aspirin for 90 days might be reasonable (Class IIb; Level of Evidence B). (New recommendation) NEJM 2011;365:993-1003; Stroke 2014:45:2160-2236 Clopidogrel Plus Aspirin: When OK ASA Guidelines 2014 Potential benefit in TIA and minor stroke when started within 24 hours as per CHANCE Might be considered for initiation within 24 hours of a minor ischemic stroke or TIA and for continuation for 90 days (Class IIb; Level of Evidence B). (New recommendation) Investigated in the US for use within 12 hours of high risk TIA or minor stroke and continued for 3 months in POINT NEJM 2013; 269:11-19; Stroke 2014;45:2160-2236; ClinicalTrials.gov

Clopidogrel Plus Aspirin ASA Stroke Prevention Guidelines 2014 The combination of aspirin and clopidogrel increases the risk of hemorrhage and is not recommended for routine long-term secondary prevention Stroke 2014;45:2160-2236 Long-Term Clopidogrel + Aspirin Fails in Stroke MATCH Trial: combination vs clopidogrel No difference in stroke/mi/death or stroke outcomes Major bleeds and life-threatening bleeds significantly higher with combination treatment SPS3 Trial: combination vs aspirin in lacunes Terminated early due to risks and futility Risk of major hemorrhage nearly doubled with dual antiplatelet therapy and mortality increased Lancet 2004;364:331-37; NEJM 2012;367:817-25

Risk Factor Control ASA Stroke Prevention Guidelines 2014 Blood pressure goal <140/90 For recent lacunar stroke, a target systolic of <130 mm Hg may be reasonable Intensive lipid lowering therapy if stroke of presumed atherosclerotic origin Smoking cessation, no heavy alcohol use Moderate exercise Stroke 2014;45:2160-2236 Patient Case: Patient With Previous Stroke Needs Surgery Mr. M. needs surgery for his broken hip. However, he had a mild stroke 3 months ago and is on aspirin. Does stopping aspirin increase his risk of stroke in the weeks following surgery? 1) Yes 2) No

Antithrombotic Medications: Neurology Guidelines Aspirin Discontinuation probably is associated with increased stroke and TIA risk Relative risk 1.97 if stopped for 2 weeks Clopidogrel, ticlopidine or aspirin/dipyridamole Insufficient evidence regarding peri-procedural use Neurol 2013;80:2065-2069 Are There Markers of Increased Stroke Risk With Surgery?

Perioperative Ischemic Stroke Risk Rates Surgery Stroke risk (%) General surgery 0.2 General surgery with or without carotid bruit 0.5 General surgery after prior stroke 7 2.9 General surgery w/ carotid stenosis and bruit or prior sxs 3.6 CABG prospective studies 1 2.0 CABG surgery after prior stroke or TIA 1 8.5 CABG surgery + valve surgery 1 4.2-13.0 CABG surgery + unilateral >50% carotid stenosis 1 3.0 CABG surgery + bilateral >50% carotid stenosis 1 5.0 CABG surgery + carotid occlusion 1 7.0 Surgery with symptomatic vertebrobasilar stenosis 2 6.0 Mayo Clin Proc 2004;79:223-229 Risks Specifically With Hip Surgery Danish study of total hip replacement n=66,583 4.7-fold risk of ischemic stroke and 4.4-fold risk of hemorrhagic stroke in the first 2 weeks after hip surgery Those patients that had been on an antiplatelet in the outpatient setting had a 70% decreased risk of ischemic stroke 6 weeks post surgery (no effect on ICH) Stroke 2012;43:3225-3229

But Can Aspirin Be Continued During Surgery? Patient Case: Patient With Previous Stroke Needs Hip Surgery Are the bleeding risks with hip surgery low enough that he can continue the aspirin? 1) Yes 2) No

Bleeding Risk Table: Aspirin and Warfarin Neurol 2013;80:2065-2069 Should Any Other Management Occur Prior to Surgery in a Stroke Patient?

Patient Case: Patient With Previous Stroke Needs Hip Surgery The patient has known asymptomatic carotid stenosis. Does the patient need carotid revascularization prior to his hip surgery? 1) Yes 2) No Preoperative Approaches Patients with stroke or TIA Evaluate for mechanism if surgery is not urgent Treat symptomatic carotid stenosis with CEA or CAS Allow a month to elapse if moderately large stroke Asymptomatic carotid stenosis Does not require surgery with CEA or CAS before general surgery In selected patients (bilateral stenosis or contralateral occlusion) having CABG, consider CAS first Mayo Clin Proc 2004;79:223-229

Should All Patients on Warfarin Be Bridged Before Surgery? Antithrombotic Medications: Neurology Guidelines Warfarin Discontinuation risk hard to assess because of varying anticoagulation indications in subjects Thromboembolic risk increased if stopped for 7 days in one study Non-warfarin oral anticoagulants Insufficient evidence regarding periprocedural use Neurol 2013;80:2065-2069

Antithrombotic Medications: CHEST Guidelines for Warfarin Interruption Warfarin In patients with a mechanical heart valve, atrial fibrillation or VTE at high risk for thromboembolism, we suggest bridging anticoagulation instead of no bridging during interruption of VKA therapy (Grade 2C) In atrial fibrillation, CHADS2 score is used for risk stratification Chest 2012;141(2 suppl):e326s-e350s Patient Case: Acute Stroke tpa or More? Mr. C., a 75 year-old, had the sudden onset of vertigo, dysconjugate gaze, right face and left body weakness on the wards 15 minutes ago. He does not have increased bleeding risks. Which treatment should be considered? 1) IV tpa 2) IV tpa and endovascular therapy 3) Endovascular therapy alone

Intravenous Thrombolysis IV tpa 0-3 hours FDA approved IV tpa 3-4.5 hours not approved by FDA but AHA/ASA science advisory and acute stroke treatment guidelines support its use Additional treatment exclusions apply NEJM 2008;359:1317-29; Stroke 2009; 40: 2945-8; Stroke 2013;44:870-947 Intra-Arterial Thrombolysis PROACT II showed the benefit of IA pro-urokinase compared to heparin in MCA occlusions but a confirmatory trial was not done Stroke 1999;282:2003-2011

What is the Controversy Regarding Endovascular Therapy? IMS III Randomized Trial IV tpa within 3 hrs vs. combined IV tpa + IA tx NIHSS 10 Baseline CTA not required, but if done needed to show occlusion in M1, ICA or basilar IA treatments included either IA tpa or mechanical embolectomy: Merci Retriever, Penumbra System, Solitaire (4 cases only) or EKOS System NEJM 2013; 368:893-903

IMS III Randomized Trial Enrollment Stopped Early for Futility (n=656) Similar outcomes in both groups: Functional independence, mrs 0-2, 40.8% with endovascular treatment versus 38.7% with IV tpa (95% CI -6.1-9.1) Similar after adjustment for the NIHSS score, or those with NIHSS 20 or 19 Mortality at 90 days, 19.1% and 21.6% (p=0.52) Symptomatic ICH, 6.2% and 5.9% (p=0.83) NEJM 2013; 368:893-903 IMS III: Questions Unknown if large vessel occlusion was present Baseline CTA that showed occlusion in only 43% Old technologies used for embolectomy Stent retrievers only used in 4 cases Bias in cases included by criteria or choice? Median baseline NIHSS of 16-17 lower than in recent embolectomy trials (NIHSS 18-19)

So When Should I Push for Endovascular Treatment in My Acute Stroke Patient? ASA Acute Stroke Guidelines 2013 Intra-arterial fibrinolysis or mechanical thrombectomy is reasonable in patients who have contraindications to the use of intravenous fibrinolysis (Class IIa; Level of Evidence C). Rescue intra-arterial fibrinolysis or mechanical thrombectomy may be reasonable approaches to recanalization in patients with large-artery occlusion who have not responded to intravenous fibrinolysis. Additional randomized trial data are needed (Class IIb; Level of Evidence B). (New recommendation) Stroke 2013; 44:870-947

One Treatment Selection Paradigm Consider IV tpa in all eligible patients Patients with large vessel occlusion that are not tpa candidates are considered for embolectomy Vertebro-basilar occlusions are considered for both IV tpa and embolectomy since mortality is 80% without treatment Certain patients with ICA or M1 occlusions also considered for both tpa and embolectomy Use of Imaging to Select Patients for Endovascular Treatment

Target Mismatch Pattern Before Treatment <100 cc After Intra-arterial Therapy ASPECTS Scale Alberta Stroke Program Early CT Score One point is subtracted from 10 for any evidence of early ischemic change for each of the defined regions Score of 7 associated with poor functional outcome and symptomatic ICH www.aspectsinstroke.com

One US Embolectomy Trial in Progress SWIFT PRIME IV tpa (4.5 hrs) versus IV tpa plus embolectomy Age 18-80 Intracranial ICA or M1 only ASPECTS <6 by imaging (few early ischemic changes) Covidien; ClinicalTrials.gov 54 y/o Woman Found at 10 AM: Last Known At Baseline Previous Evening Found by family at 10 AM sitting dressed in chair Had spoken with husband by phone previous evening Telestroke exam Near plegia on right, mute NIHSS=21 Outside CT 11:22 AM unremarkable

54 y/o Woman Found at 10 AM 54 y/o Woman Found at 10 AM Not a tpa candidate, treated with embolectomy Pre treatment Recanalized after one pass with Trevo device at 14:36

54 y/o Woman Found at 10 AM MRI at 10:51 PM showed lesion has not grown appreciably; NIHSS=5 (dysarthria, drift, neglect) By the following AM, NIHSS=1 for right naso-labial fold flattening DWI Any New Recommendations for Supportive Treatments in Acute Stroke?

Supportive Measures for Acute Stroke: ASA Guidelines 2013 Optimal blood pressure still unknown Consensus to withhold treatment unless >220/120, if the patient is not receiving therapies to recanalize vessels Can restart medications at 24 hours if the patient is stable Treat fever and underlying causes Hypothermia has not yet been assessed in Phase 3 trials Supplemental oxygen not routinely recommended Maintain saturations at > 94% Stroke 2013; 44:870-947